Sagimet Biosciences (SGMT) Share-based Compensation (2022 - 2026)

Sagimet Biosciences' Share-based Compensation history runs 5 years deep, the most recent figure standing at $9.9 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 572.55% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $9.9 million (up 1048.49% YoY), while the FY2025 annual figure was $8.3 million, down 2.35% from the prior year.
• Share-based Compensation for Q1 2026 stood at $9.9 million, up from $9.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $9.9 million in Q1 2026, with the low at -$3.6 million in Q4 2024.
• The 5-year median for Share-based Compensation is $1.1 million (2023), against an average of $1.8 million.
• The sharpest annual moves came in 2024 and 2026: Share-based Compensation plunged 374.98% in 2024, then surged 572.55% in 2026.
• Sagimet Biosciences' Share-based Compensation stood at $721000.0 in 2022, then jumped by 81.83% to $1.3 million in 2023, then slumped by 374.98% to -$3.6 million in 2024, then surged by 360.75% to $9.4 million in 2025, then climbed by 5.32% to $9.9 million in 2026.
• Business Quant data shows SGMT's Share-based Compensation at $9.9 million in Q1 2026, $9.4 million in Q3 2025, and $1000.0 in Q2 2025.